These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 30071046)

  • 1. Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin.
    Thorpe CM; Kane AV; Chang J; Tai A; Vickers RJ; Snydman DR
    PLoS One; 2018; 13(8):e0199810. PubMed ID: 30071046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response.
    Okhuysen PC; Ramesh MS; Louie T; Kiknadze N; Torre-Cisneros J; de Oliveira CM; Van Steenkiste C; Stychneuskaya A; Garey KW; Garcia-Diaz J; Li J; Duperchy E; Chang BY; Sukbuntherng J; Montoya JG; Styles L; Clow F; James D; Dubberke ER; Wilcox M
    Clin Infect Dis; 2024 Jun; 78(6):1462-1472. PubMed ID: 38305378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ridinilazole: a novel therapy for Clostridium difficile infection.
    Vickers RJ; Tillotson G; Goldstein EJ; Citron DM; Garey KW; Wilcox MH
    Int J Antimicrob Agents; 2016 Aug; 48(2):137-43. PubMed ID: 27283730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ridinilazole for the treatment of Clostridioides difficile infection.
    Carlson TJ; Endres BT; Bassères E; Gonzales-Luna AJ; Garey KW
    Expert Opin Investig Drugs; 2019 Apr; 28(4):303-310. PubMed ID: 30767587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
    Collins DA; Riley TV
    Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial susceptibility and ribotypes of Clostridium difficile isolates from a Phase 2 clinical trial of ridinilazole (SMT19969) and vancomycin.
    Snydman DR; McDermott LA; Thorpe CM; Chang J; Wick J; Walk ST; Vickers RJ
    J Antimicrob Chemother; 2018 Aug; 73(8):2078-2084. PubMed ID: 29718329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.
    Vickers RJ; Tillotson GS; Nathan R; Hazan S; Pullman J; Lucasti C; Deck K; Yacyshyn B; Maliakkal B; Pesant Y; Tejura B; Roblin D; Gerding DN; Wilcox MH;
    Lancet Infect Dis; 2017 Jul; 17(7):735-744. PubMed ID: 28461207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
    Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
    Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ridinilazole, a narrow spectrum antibiotic for treatment of
    Qian X; Yanagi K; Kane AV; Alden N; Lei M; Snydman DR; Vickers RJ; Lee K; Thorpe CM
    Am J Physiol Gastrointest Liver Physiol; 2020 Aug; 319(2):G227-G237. PubMed ID: 32597706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model of Clostridium difficile Infection.
    van Opstal E; Kolling GL; Moore JH; Coquery CM; Wade NS; Loo WM; Bolick DT; Shin JH; Erickson LD; Warren CA
    J Infect Dis; 2016 Jul; 214(1):130-9. PubMed ID: 26917573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
    Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
    mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
    [No Abstract]   [Full Text] [Related]  

  • 12. The gut microbiome diversity of Clostridioides difficile-inoculated mice treated with vancomycin and fidaxomicin.
    Yamaguchi T; Konishi H; Aoki K; Ishii Y; Chono K; Tateda K
    J Infect Chemother; 2020 May; 26(5):483-491. PubMed ID: 32165071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
    Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
    Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional and Metagenomic Evaluation of Ibezapolstat for Early Evaluation of Anti-Recurrence Effects in Clostridioides difficile Infection.
    McPherson J; Hu C; Begum K; Wang W; Lancaster C; Gonzales-Luna AJ; Loveall C; Silverman MH; Alam MJ; Garey KW
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0224421. PubMed ID: 35862742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clearance of Clostridioides difficile Colonization Is Associated with Antibiotic-Specific Bacterial Changes.
    Lesniak NA; Schubert AM; Sinani H; Schloss PD
    mSphere; 2021 May; 6(3):. PubMed ID: 33952668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Novel DNA Binding Mechanism of Ridinilazole, a Precision
    Mason CS; Avis T; Hu C; Nagalingam N; Mudaliar M; Coward C; Begum K; Gajewski K; Alam MJ; Bassères E; Moss S; Reich S; Duperchy E; Fox KR; Garey KW; Powell DJ
    Antimicrob Agents Chemother; 2023 May; 67(5):e0156322. PubMed ID: 37093023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced Vancomycin Susceptibility in Clostridioides difficile Is Associated With Lower Rates of Initial Cure and Sustained Clinical Response.
    Eubank TA; Dureja C; Garey KW; Hurdle JG; Gonzales-Luna AJ
    Clin Infect Dis; 2024 Jul; 79(1):15-21. PubMed ID: 38382090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences of the Fecal Microflora With Clostridium difficile Therapies.
    Louie TJ; Byrne B; Emery J; Ward L; Krulicki W; Nguyen D; Wu K; Cannon K
    Clin Infect Dis; 2015 May; 60 Suppl 2():S91-7. PubMed ID: 25922407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clostridioides difficile - New Insights and Therapy Recommendations].
    Schönherr S; Jung L; Lübbert C
    Dtsch Med Wochenschr; 2023 Jun; 148(12):752-758. PubMed ID: 37257477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
    Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.